Aspen Neuroscience, Inc. Form S-1/A — Oct 26, 2026
Aspen Neuroscience filed Amendment No. 2 to its S-1 for an IPO of 9,375,000 shares priced at $15.00-$17.00 per share, with underwriters led by Leerink Partners and UBS Investment Bank, listing on Nasdaq under ticker ASPE. Estimated net proceeds are approximately $134.5 million at the $16.00 midpoint, or $155.4 million if the 1,406,250-share greenshoe is exercised in full. The clinical-stage biotech is developing sasineprocel, an autologous iPSC-derived cell therapy for Parkinson's disease, currently in an open-label Phase 1/2a ASPIRO trial with 15 patients dosed and encouraging interim data; Phase 3 biopsy collection is anticipated by end of 2026 with dosing in the second half of 2027.
Key figures
- Eps
- -$33.39 (six months 2026, pre-split); -$1.86 pro forma
- Net Income
- -$36.5 million for six months ended June 30, 2026; -$62.1 million FY2025
- Total Debt
- $22.5 million total liabilities
- Total Assets
- $110.3 million (June 30, 2026)
- Cash Position
- $72.4 million (June 30, 2026)
- Gross Proceeds
- approximately $134.5 million net (or ~$155.4 million with full greenshoe), based on $16.00 midpoint
- Offering Price
- $15.00 - $17.00 per share
- Shares Offered
- 9375000
- Greenshoe Shares
- 1406250
- Cash Runway Post IPO
- into the second half of 2028
- Reverse Split Ratio
- 1-for-9.8821 (effected October 23, 2026)
- Shares Pre Offering
- 19703600
- Accumulated Deficit
- $264.9 million
- Prior Capital Raised
- $347 million
- Shares Outstanding Post Offering
- 29,078,600 (or 30,484,850 with greenshoe)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.